China Bao Tai

Baotai Biopharmaceutical is a clinical-stage Chinese biotechnology company specializing in the development of high-valence vaccines, particularly for Human Papillomavirus (HPV). The company is most recognized for its flagship candidate, BTP-04, which is the world's first 14-valent HPV vaccine to enter Phase 3 clinical trials. This vaccine is designed to provide significantly broader protection against cervical cancer and other HPV-related diseases compared to existing 2-valent, 4-valent, and 9-valent vaccines. Baotai utilizes a proprietary recombinant protein expression and virus-like particle (VLP) assembly platform to ensure high purity and immunogenicity of its products. Headquartered in Beijing, the company aims to address critical public health gaps in China and international markets through innovative vaccine technology.